Chimeric antigen receptor (CAR) T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma (DLBCL), with research now exploring ways to shift these agents earlier in the treatment paradigm, according to a discussion at the 2nd Annual Live Medical Crossfire on Hematologic Malignancies. The quick arrival of...Continue Reading

Promising clinical trial data have highlighted advances in the treatment of mantle cell lymphoma (MCL), but an important next step is applying this progress to routine clinical practice, said Andre Goy, MD. These recent data have not only suggested that patients with MCL can expect a better quality of life with novel therapies, but also...Continue Reading